Published 24 July 2008, doi:10.1136/bmj.a979
Cite this as: BMJ 2008;337:a979

News

Cancer expert doubts claims about prostate cancer trial

Andrew Cole

1 London

The first 150 words of the full text of this article appear below.

A leading clinical oncologist has raised questions about claims that a new drug could treat as many as 80% of men diagnosed as having the most aggressive and previously drug resistant form of prostate cancer.

The results of the phase I clinical trial by the Institute of Cancer Research and the Royal Marsden Hospital, showed significant tumour shrinkage and big falls in prostate specific antigen (PSA) concentrations in most of the 21 men with advanced prostate cancer who received the drug abiraterone acetate (Journal of Clinical Oncology 2008 Jul 21; doi: 10.1200/JCO.2007.15.9749).

But Nick James, professor of clinical oncology at Birmingham University, said that it was far too early to know whether these initial results had any long term importance.

"I have been involved in two trials relating to prostate cancer in the last year," he said. "In one of the trials there was absolutely no PSA effect . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Prostate cancer’s day in the sun
Gerhardt Attard, Alison H Reid, David Dearnaley, and Johann S De Bono
BMJ 2008 337: a1249. [Extract] [Full Text]

This article has been cited by other articles:

  • Attard, G., Reid, A. H, Dearnaley, D., Bono, J. S D. (2008). Prostate cancer's day in the sun. BMJ 337: a1249-a1249 [Full text]  

Rapid Responses:

Read all Rapid Responses

Prostate Cancer’s Day in the Sun
Gerhardt Attard, et al.
bmj.com, 31 Jul 2008 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ